ARDELYX, INC.·4

May 23, 4:19 PM ET

Rosenbaum David P. 4

4 · ARDELYX, INC. · Filed May 23, 2024

Insider Transaction Report

Form 4
Period: 2024-05-21
Rosenbaum David P.
SVP, Drug Development
Transactions
  • Sale

    Common Stock

    2024-05-21$7.81/sh4,855$37,922376,479 total
  • Sale

    Common Stock

    2024-05-21$7.81/sh2,198$17,169176,374 total(indirect: By Spouse)
Holdings
  • Common Stock

    (indirect: By Trust)
    77,592
Footnotes (5)
  • [F1]Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
  • [F2]Reflects the adjusted total which includes the purchase of 2,349 shares under the Ardelyx Employee Stock Purchase Plan in February 2024.
  • [F3]Reflects the adjusted total which includes the purchase of 2,636 shares under the Ardelyx Employee Stock Purchase Plan in February 2024.
  • [F4]The shares are directly held by the Reporting Person's wife.
  • [F5]The shares are directly held by David Paul Rosenbaum and Susan Edelstein Rosenbaum, Trustees of the David Paul Rosenbaum Family Trust.

Documents

1 file
  • 4
    wk-form4_1716495544.xmlPrimary

    FORM 4